Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in AMYT?
Amryt Pharmaceuticals: THE INVESTMENT CASE

Amryt Pharma drug exceeds expectations; potential market bigger than anticipated

Lead product Lojuxta generated revenues of €5.75mln in the first-half
woman at a microscope
INVESTMENT OVERVIEW: AMYT The Big Picture
There is currently a lot of excitement around AP101, which is undergoing phase III clinical trials

Amryt Pharma PLC (LON:AMYT) said a product that it licensed the rights to is performing better than expected.

Lojuxta treats a rare and life-threatening condition called Homozygous Familial Hypercholesterolemia, which causes abnormally high levels of bad cholesterol.

WATCH: Lojuxta 'exceeding expectations', says Amryt Pharma's Joe Wiley

Revenues from the treatment were €5.75mln for the six months ended June; the company’s total sales for the period were €6.18mln.

Addressable market bigger than expected

Amryt thinks Lojuxta’s addressable market is €100mln in the EU and other territories where it holds the rights, which, according to chief executive Joe Wiley “is larger than we originally anticipated”.

“A major focus for us looking forward is opening up new, untapped territories covered by our licence agreement,” he added.

The company said it is currently in the process of putting in place the commercial, medical and regulatory infrastructure to support additional products it is developing or might bring in.

Lot of excitement 

There is currently a lot of excitement around AP101, described as Amryt’s “lead asset”.

Created to treat Epidermolysis Bullosa, a condition where the skin is fragile to the faintest contact, it is currently undergoing phase III clinical trials.

An interim data read-out is expected in the first half of next year. The successful completion of the full study could see AP101 fast-tracked as an orphan drug, which treats an unmet medical need.

The firm estimates the medication’s potential market to be in excess of €1.3bn worldwide.

Preclinical progress

Its preclinical innovation, AP102 for rare neuroendocrine diseases, remains on track for human trials next year.

As is common for a company at Amyrt’s formative stage of commercial development, the business was unprofitable in the six months under review. The operating loss was €5.79mln.

More importantly, it is financially well endowed with €10.9mln cash on hand as at the end of June. It also has a debt facility it can call on.

"The company has achieved significant milestones in the first half of 2017 and we remain confident of continuing strong progress over the remainder of 2017 and into 2018," said CEO Wiley.

Truly impressive 

The shares, up 21% in the last year, marked time at 22p.

City broker Beaufort is a fan, lifting its price target to 65p a share from 62p.

It pointed out the company’s current market worth is currently less than the prudently discounted value of Lojuxta.

“[Amryt is] delivering on every promise and more,” Beaufort said in a not to clients.

“This truly impressive half-year report highlights a management very much in control of an ambitious programme that spreads across a multiple rare diseases, meeting or exceeding best expectations in every case.”

---adds share price and broker comment---

View full AMYT profile View Profile

Amryt Pharmaceuticals Timeline

Related Articles

researcher using microscope
September 28 2017
A total of £6mln is expected to come via a share placing and up to a further £2mln through an open offer of stock to existing investors
woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use